Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 14, 2023 | -$0.38 | -$0.39 | Miss |
| Aug 10, 2023 | -$0.56 | -$0.49 | Beat |
| May 10, 2023 | -$0.56 | -$0.54 | Beat |
| Mar 29, 2023 | -$0.54 | -$0.55 | Miss |
| Nov 10, 2022 | -$0.73 | -$0.60 | Beat |
| Aug 8, 2022 | -$0.70 | -$0.72 | Miss |